# MARS2: HCP commentary report

> 165 HCP sources screened · 1094 verified claims from 134 sources · 12 findings. Updated 2026-10-08.

## Report

- Trial: Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2).
- NCT ID: NCT02040272
- Registry: https://clinicaltrials.gov/study/NCT02040272
- Sponsor: Royal Brompton & Harefield NHS Foundation Trust
- Phase: Not applicable
- Status: Unknown
- Indications: Mesothelioma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-08
- Last checked: 2026-10-08
- Release hash: 290b3332d75649e30eaf65b95ff0aa9a2bbf2fa29b20c6a08b2971a3aad890fe

## Counts

- HCP commentary sources screened: 165
- Sources cited by verified claims: 134
- Verified claims: 1,094
- Findings: 12
- People found in screened sources: 141
- People identity-verified: 114
- Voices cited: 98

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

MARS 2 frames clinicians’ central question: should lung-sparing surgery be added to chemotherapy for people with pleural mesothelioma, and in what circumstances? Discussion covers patient selection, staging and tissue diagnosis, operative extent and center expertise, survival analysis, chemotherapy sequencing and completion, and systemic or radiotherapy alternatives. Other topics include treatment deferral and holds, quality of life, informed choice, costs, specialist referral, drug access, regional applicability, trial design and safety oversight.

## Open Medical Affairs question

What evidence threshold do clinicians require before offering selected surgery outside a trial, and how do they distinguish an exception from routine practice?

## Findings (titles)

- F1. The central dispute is whether selected surgery can continue outside research—not whether surgery should remain routine
- F2. Changing the surgical decision can change drug access, referral, staging and diagnostic behavior
- F3. Early-stage epithelioid selection is a proposed exception, not a demonstrated rescue of surgery
- F4. Systemic-treatment delivery is debated as both a competing explanation and a consequence of surgery
- F5. Expertise arguments intersect with operative extent, diaphragm loss and recovery—not just center volume
- F6. Survival language and crossing-curve analysis are genuine points of disagreement
- F7. Quality time, costs and informed choice matter alongside survival—and patient preference does not compel an operation
- F8. Systemic treatment is a favored alternative, but histology, toxicity and conditions for holding treatment remain important
- F9. Radiotherapy is raised as a next step, but safety, treatment setting and appropriate observation limit the enthusiasm
- F10. Intraoperative adjuncts expose a distinct disagreement about benefit, renal harm and unproven less-radical approaches
- F11. Global implementation depends on diagnostic concentration, specialist capacity and the feasibility of generating local evidence
- F12. Praise for randomized evidence coexists with concern about bias, recruitment communication and the treatment of dissent

## Sample findings

### F4. Systemic-treatment delivery is debated as both a competing explanation and a consequence of surgery

A podcast host asked whether differing use of postoperative chemotherapy could weaken the MARS 2 comparison, or whether its importance was limited relative to the operation itself.

Source: podcast, 2024-05-01.

### F5. Expertise arguments intersect with operative extent, diaphragm loss and recovery—not just center volume

A podcast moderator asked whether the independent monitoring committee had assessed interim data and whether safety concerns warranted stopping the study earlier.

Source: podcast, 2023-09-26.

## Trial aspects

| Aspect | Coverage | Claims | Sources |
| --- | --- | ---: | ---: |
| Routine, experimental and exceptional use of cytoreductive surgery | discussed | 26 | 17 |
| Resectability labels, systemic-treatment access and specialist referral | discussed | 22 | 7 |
| Histology, early-stage selection, fitness and proposed biomarkers | discussed | 44 | 13 |
| Imaging, invasive staging and tissue acquisition | discussed | 64 | 8 |
| Chemotherapy sequence, completion and subsequent treatment | discussed | 39 | 9 |
| Operative extent, quality assurance, mortality and oversight | discussed | 48 | 12 |
| Survival estimands, late curve crossing and harm terminology | discussed | 28 | 17 |
| Quality of life, costs, meaningful benefit and patient choice | discussed | 44 | 13 |
| Systemic alternatives and conditions for deferral or treatment holds | discussed | 38 | 16 |
| Radiotherapy, surveillance and multimodality sequencing | discussed | 30 | 6 |
| Intraoperative adjuncts and less-radical local approaches | discussed | 24 | 4 |
| Regional implementation and evidence-generation capacity | discussed | 54 | 9 |
| Randomized evidence, recruitment equipoise and cross-specialty debate | discussed | 69 | 27 |

## Cited sources by channel

- Podcasts: 22
- Publications: 3
- X threads: 102
- YouTube: 7

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice.

- Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- 24 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
- 5 further source limits are recorded in the machine-readable scope of this record.
- The evidence describes reviewed commentary, not a representative survey of HCP opinion, guideline adoption or surgical utilization.
- Multiple sources may repeat the same person, event or discussion; source counts must not be interpreted as independent clinician counts.
- Some statements are reported opinions, patient recollections, institutional accounts or anecdotal experiences rather than direct clinician testimony or controlled evidence.
- Uncertain speakers remain unnamed; adjacent named contributions do not establish who spoke a continuation.
- Some accounts use inconsistent procedure names, endpoint descriptions or numerical wording. They are retained as commentary rather than silently corrected into trial facts.
- Several subgroup and cross-study interpretations lack effect estimates, uncertainty intervals or appropriate nonsurgical comparisons in the cited passages.
- Treatment-access, professional-context and practice descriptions are source- and time-specific, not current global verification.
- The recruitment publication did not interview over one-third of approached professionals and lacked consultation recordings from half the study sites.
- Searches may have missed unnamed trial references or transcription variants, and five identified videos could not be reviewed.
- One podcast's available transcript leaves some speaker identities uncertain; this limits attribution but does not justify assigning those views to rostered participants.

## Offer

- Size: Deep (131 commentary sources cited)
- Current edition: $1,950. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (114 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/mars2-nct02040272
- Agents: POST https://www.erudio.com/api/orders with {"report": "mars2-nct02040272", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=mars2-02040272

## Cite

Erudio Health. MARS2 (NCT02040272): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-08. https://www.erudio.com/reports/mars2-nct02040272

## Machine access

- JSON: https://www.erudio.com/reports/mars2-nct02040272.json
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "mars2-02040272"}`